This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot2: STU1 Ballot 2) based on FHIR (HL7® FHIR® Standard) v6.0.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions
@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix sct: <http://snomed.info/id/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
# - resource -------------------------------------------------------------------
a fhir:Group ;
fhir:nodeRole fhir:treeRoot ;
fhir:id [ fhir:v "179619"] ; #
fhir:meta [
fhir:versionId [ fhir:v "5" ] ;
fhir:lastUpdated [ fhir:v "2025-03-15T21:15:32.464Z"^^xsd:dateTime ] ;
( fhir:profile [
fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-eligibility-criteria"^^xsd:anyURI ;
fhir:link <http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-eligibility-criteria> ] )
] ; #
fhir:text [
fhir:status [ fhir:v "empty" ] ;
fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"^^rdf:XMLLiteral
] ; #
fhir:extension ( [
fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/artifact-author"^^xsd:anyURI ] ;
fhir:value [
a fhir:ContactDetail ;
fhir:name [ fhir:v "Brian S. Alper" ] ]
] [
fhir:url [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as"^^xsd:anyURI ] ;
fhir:value [
a fhir:markdown ;
fhir:v "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179619. Revised 2023-12-06. Available at: https://fevir.net/resources/Group/179619. Computable resource at: https://fevir.net/resources/Group/179619#json." ]
] ) ; #
fhir:url [ fhir:v "https://fevir.net/resources/Group/179619"^^xsd:anyURI] ; #
fhir:identifier ( [
fhir:type [
( fhir:coding [
fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/v2-0203"^^xsd:anyURI ] ;
fhir:code [ fhir:v "ACSN" ] ;
fhir:display [ fhir:v "Accession ID" ] ] ) ;
fhir:text [ fhir:v "FEvIR Object Identifier" ] ] ;
fhir:system [ fhir:v "urn:ietf:rfc:3986"^^xsd:anyURI ] ;
fhir:value [ fhir:v "https://fevir.net/FOI/179619" ] ;
fhir:assigner [
fhir:display [ fhir:v "Computable Publishing LLC" ] ]
] ) ; #
fhir:name [ fhir:v "SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer"] ; #
fhir:title [ fhir:v "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"] ; #
fhir:status [ fhir:v "active"] ; #
fhir:publisher [ fhir:v "Computable Publishing LLC"] ; #
fhir:contact ( [
( fhir:telecom [
fhir:system [ fhir:v "email" ] ;
fhir:value [ fhir:v "support@computablepublishing.com" ] ] )
] ) ; #
fhir:description [ fhir:v "**Study selection criteria**\nTypes of Studies.\nRandomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone.\n\nTypes of participants.\nPatients aged ≥18 years with cytological or histological diagnosis of mHNPC."] ; #
fhir:useContext ( [
fhir:code [
fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ;
fhir:code [ fhir:v "evidence-communication" ] ;
fhir:display [ fhir:v "Evidence Communication" ] ] ;
fhir:value [
a fhir:CodeableConcept ;
( fhir:coding [
fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ;
fhir:code [ fhir:v "SystematicReviewEligibilityCriteria" ] ;
fhir:display [ fhir:v "SystematicReviewEligibilityCriteria" ] ] ) ]
] ) ; #
fhir:copyright [ fhir:v "https://creativecommons.org/licenses/by-nc-sa/4.0/"] ; #
fhir:membership [ fhir:v "conceptual"] ; #
fhir:combinationMethod [ fhir:v "all-of"] ; #
fhir:characteristic ( [
fhir:code [
fhir:text [ fhir:v "Study Design" ] ] ;
fhir:value [
a fhir:CodeableConcept ;
( fhir:coding [
fhir:system [ fhir:v "https://fevir.net/sevco"^^xsd:anyURI ] ;
fhir:code [ fhir:v "SEVCO:01003" ] ;
fhir:display [ fhir:v "randomized assignment" ] ] ) ] ;
fhir:exclude [ fhir:v false ] ;
fhir:description [ fhir:v "Randomized controlled clinical trials (RCTs)" ]
] [
fhir:code [
fhir:text [ fhir:v "Study Design" ] ] ;
fhir:value [
a fhir:CodeableConcept ;
( fhir:coding [
fhir:system [ fhir:v "https://fevir.net/sevco"^^xsd:anyURI ] ;
fhir:code [ fhir:v "SEVCO:01011" ] ;
fhir:display [ fhir:v "Parallel cohort design" ] ] ) ] ;
fhir:exclude [ fhir:v false ] ;
fhir:description [ fhir:v "parallel design" ]
] [
fhir:code [
fhir:text [ fhir:v "Comparison" ] ] ;
fhir:value [
a fhir:Reference ;
fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ;
fhir:display [ fhir:v "GroupAssignment: ADT plus docetaxel vs. ADT alone" ] ] ;
fhir:exclude [ fhir:v false ] ;
fhir:description [ fhir:v "compared the association of ADT and chemotherapy (docetaxel), versus ADT alone" ]
] [
fhir:code [
( fhir:coding [
a sct:397669002 ;
fhir:system [ fhir:v "http://snomed.info/sct"^^xsd:anyURI ] ;
fhir:code [ fhir:v "397669002" ] ;
fhir:display [ fhir:v "Age" ] ] ) ] ;
fhir:value [
a fhir:Quantity ;
fhir:value [ fhir:v "18"^^xsd:decimal ] ;
fhir:comparator [ fhir:v ">=" ] ;
fhir:unit [ fhir:v "years" ] ;
fhir:system [ fhir:v "http://unitsofmeasure.org"^^xsd:anyURI ] ;
fhir:code [ fhir:v "a" ] ] ;
fhir:exclude [ fhir:v false ] ;
fhir:description [ fhir:v "Types of participants.\nPatients aged ≥18 years" ] ;
( fhir:method [
fhir:text [ fhir:v "applied to participants in the studies" ] ] )
] [
fhir:code [
( fhir:coding [
a sct:64572001 ;
fhir:system [ fhir:v "http://snomed.info/sct"^^xsd:anyURI ] ;
fhir:code [ fhir:v "64572001" ] ;
fhir:display [ fhir:v "Disease (disorder)" ] ] ) ] ;
fhir:value [
a fhir:CodeableConcept ;
fhir:text [ fhir:v "metastatic hormone-naive prostate cancer" ] ] ;
fhir:exclude [ fhir:v false ] ;
fhir:description [ fhir:v "Types of participants.\nPatients with cytological or histological diagnosis of mHNPC." ] ;
( fhir:method [
fhir:text [ fhir:v "applied to participants in the studies" ] ] [
fhir:text [ fhir:v "cytological or histological diagnosis" ] ] )
] ) . #
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot2 based on FHIR 6.0.0-ballot2. Generated 2025-03-28
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change